Lipoprotein abnormalities related to women's health

American Journal of Cardiology

Volumn 90, Issue 8 SUPPL., 2002, Pages 77-84

  Bittner, Vera ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ESTRADIOL; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; WARFARIN;

ADULTHOOD; AGE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; LIFE EXPECTANCY; LIFESPAN; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MENOPAUSAL SYNDROME; MORBIDITY; OBESITY; PARTICLE SIZE; PREDICTION; PRIORITY JOURNAL; PUBERTY; RECURRENT DISEASE; REVIEW; SEX DIFFERENCE;

EID: 0037126374     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02637-1     Document Type: Article

References (74)

1. Hazzard W.R. Why do women live longer than men? Postgrad Med. 85:1989;271-283.
2. American Heart Association . 2001 Heart and Stroke Statistical Update. 2000;American Heart Association, Dallas.
3. Lloyd-Jones D.M., Larson M.G., Beiser A., Levy D. Lifetime risk of developing coronary heart disease. Lancet. 353:1999;89-92.
4. National Cholesterol Education Program. Adult Treatment Panel III Report. 2001. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm. Accessed December 1, 2001.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Bethesda, MD: National Institutes of Health. NIH Publication No. 93-3095, September 1993.
6. Sempos C.T., Cleeman J.I., Carroll M.D., Johnson C.L., Bachorik P.S., Gordon D.J., Burt V.L., Briefel R.R., Brown C.D., Lippel K., Rifkind B.M. Prevalence of high blood cholesterol among U.S. adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA. 269:1993;3009-3014.
7. National Heart, Lung, and Blood Institute. The Lipid Research Clinics Population Studies Data Book: Volume 1 - The Prevalence Study. Bethesda, MD: US Dept of Health and Human Services, Public Health Service, National Institutes of Health. NIH Publication No. 80-1527, July 1980.
8. Freedman D.S., Bowman B.A., Srinivasan S.R., Berenson G.S., Otvos J.D. Distribution and correlates of high-density lipoprotein subclasses among children and adolescents. Metabolism. 50:2001;370-376.
9. Dobiasova M., Urbanova Z., Rauchova H., Samanek M., Frohlich J.J. High-density lipoprotein subclasses and esterification rate of cholesterol in children effect of gender and age . Acta Paediatr. 87:1998;918-923.
10. Freedman D.S., Bowman B.A., Otvos J.D., Srinivasan S., Berenson G.S. Levels and correlates of LDL and VLDL particles sizes among children the Bogalusa heart study . Atherosclerosis. 152:2000;441-449.
11. McGill H.C. Jr, McMahan A., Zieske A.W., Tracy R.E., Malcom G.T., Herderick E.E., Strong J.P., for the Pathological Determinants of Atherosclerosis in Youth (PDAY) Research Group . Association of coronary heart disease risk factors with microscopic qualities of coronary atheroscleoris in youth. Circulation. 102:2000;374-379.
12. Bao W., Srinivasan S.R., Wattigney W.A., Bao W., Berenson G.S. Usefulness of childhood low-density lipoprotein cholesterol level in predicting adult dyslipidemia and other cardiovascular risks. The Bogalusa Heart Study. Arch Intern Med. 156:1996;1315-1320.
13. Gardner C.D., Winkleby M.A., Fortmann S.P. Population frequency distribution of non-high-density lipoprotein cholesterol (Third National Health and Nutrition Examination Survey [NHANES III], 1988-1994) [NHANES III]. Am J Cardiol. 86:2000;299-304.
14. Bittner V., Simon J.A., Fong J., Blumenthal R.S., Newby K., Stefanick M.L. Correlates of high HDL cholesterol among women with coronary heart disease. Am Heart J. 139:2000;288-296.
15. Schaefer E.J., Lamon-Fava S., Cohn S.D., Schaefer M.M., Ordovas J.M., Castelli W.P., Wilson P.W. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res. 35:1994;779-792.
16. LaRosa J.C. Lipoproteins and CAD risk in women. J Myocardial Ischemia. 3:1991;35-42.
17. Sacks F.M., Walsh B.W. Sex hormones and lipoprotein metabolism. Curr Opin Lipidol. 5:1994;236-240.
18. Gosland I.F., Wynn V., Crook D., Miller N.E. Sex, plasma lipoproteins and atherosclerosis prevailing assumptions and outstanding questions . Am Heart J. 114:1997;1467-1503.
19. Greenlund K.J., Webber L.S., Srinivasan S., Wattigney W., Johnson C., Berenson G.S. Associations of oral contraceptive use with serum lipids and lipoproteins in young women the Bogalusa Heart Study . Ann Epidemiol. 7:1997;561-567.
20. Godsland I.F., Crook B.A., Simpson R., Proudler T., Felton C., Lees B., Anyaoku V., Devenport M., Wynn V. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med. 323:1990;1375-1381.
21. Foulon T., Payen N., Laporte F., Bijaoui S., Dupont G., Roland F., Groslambert P. Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size. Contraception. 64:2001;11-16.
22. Chasan-Taber L., Stampfer M. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med. 128:1998;467-477.
23. Stampfer M.J., Willett W.C., Colditz G.A., Speizer F.E., Hennekens C.H. Past use of oral contraceptives and cardiovascular disease a meta-analysis in the context of the Nurses' Health Study . Am J Obstet Gynecol. 163:1990;285-291.
24. Van Stiphout W.A.H.J., Hofman A., de Bruijn A.M. Serum lipids in young women before, during, and after pregnancy. Am J Epidemiol. 126:1987;922-928.
25. Akahoshi M., Soda M., Nakashima E., Shimaoka K., Seto S., Yano K. Effects of menopause on trends of serum cholesterol, blood pressure and body mass index. Circulation. 94:1996;61-66.
26. Hjortland M.C., McNamara P.M., Kannel W.B. Some atherogenic concomitants of menopause the Framingham Study . Am J Epidemiol. 103:1976;304-311.
27. Van Beresteijn E.C.H., Korevaar J.C., Huijbregts P.C.W., Schouten E.G., Burema J., Kok F.J. Perimenopausal increase in serum cholesterol a 10-year longitudinal study . Am J Epidemiol. 137:1993;383-392.
28. Do K.A., Green A., Guthrie J.R., Dudley E.C., Burger H.G., Denerstein L. Longitudinal study of risk factors for coronary heart disease across the menopausal transition. Am J Epidemiol. 151:2000;584-593.
29. Matthews K.A., Meilahn E., Kuller L.H., Kelsey S.F., Caggiula A.W., Wing R.R. Menopause and risk factors for coronary heart disease. N Engl J Med. 321:1989;641-646.
30. Mathews K.A., Wing R.R., Kuller L.H., Meilahn E.N., Plantinga P. Influence of the perimenopause on cardiovascular risk factors and symptoms of middle-aged healthy women. Arch Intern Med. 154:1994;2349-2355.
31. Campos H., McNamara J.R., Wilson P.W.F., Ordovas J.M., Schaefer E.J. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab. 67:1988;30-35.
32. Carr M.C., Kim K.H., Zambon A., Mitchell E.S., Woods N.F., Casazza C.P., Purnell J.Q., Hokanson J.E., Brunzell J.D., Schwartz R.S. Changes in LDL density across the menopausal transition. J Invest Med. 48:2000;245-250.
33. Bittner V. Atherogenicity of postprandial lipoproteins and coronary heart disease. Endocrinologist. 4:1994;359-372.
34. Van Beek A.P., de Ruijter-Heijstek F.C., Erkelens D.W., de Bruin T.W.A. Menopause is associated with reduced protection from postprandial lipemia. Arterioscler Thromb Vasc Biol. 19:1999;2737-2741.
35. Godsland I.F. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations analysis of studies published from 1974-2000 . Fertil Steril. 75:2001;898-915.
36. The Writing Group for the PEPI Trial . Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 273:1995;199-208.
37. Espeland M.A., Marcovina S.M., Miller V., Wood P.D., Wasilauskas C., Sherwin R., Schrott H., Bush T.L., for the PEPI investigators . Effect of postmenopausal hormone therapy on lipoprotein (a) concentration. Circulation. 97:1998;979-986.
38. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E., for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group . Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 280:1998;605-613.
39. Shlipak M.G., Simon J.A., Vittinghoff E., Lin F., Barrett-Connor E., Knopp R.H., Levy R.I., Hulley S.B. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart events after menopause. JAMA. 283:2000;1845-1852.
40. Weintraub M.S., Grosskopf I., Charach G., Eckstein N., Ringel Y., Maharshak N., Rotmensch H.H., Rubinstein A. Fluctuations of lipid and lipoprotein levels in hyperlipidemic postmenopausal women receiving hormone replacement therapy. Arch Intern Med. 158:1998;1803-1806.
41. Ory S.J., Field C.S., Herrmann R.R., Zinsmeister A.R., Riggs B.L. Effects of long-term transdermal administration of estradiol on serum lipids. Mayo Clin Proc. 73:1998;735-738.
42. Tsuda M., Sanada M., Nakagawa H., Kodama I., Sakashita T., Ohama K. Phenotype of apolipoprotein E influences the lipid metabolic response of postmenopausal women to hormone replacement therapy. Maturitas. 38:2001;297-304.
43. Legault C., Stefanick M.L., Miller V.T., Marcovina S.M., Schrott H.G. Effect of hormone replacement therapy on the validity of the Friedewald equation in postmenopausal women the Postmenopausal Estrogen/Progestins Interventions (PEPI) Trial . J Clin Epidemiol. 52:1999;1187-1195.
44. Alexanderson P., Haarbo J., Christiansen C. Impact of combined hormone replacement therapy on serum lipid metabolism new aspects . Gynecol Endocrinol. 11:1997;281-288.
45. Wakatsuki A., Ikenoue N., Okatani Y., Fukaya T. Estrogen-induced small low density lipoprotein particles may be atherogenic in postmenopausal women. J Am Coll Cardiol. 37:2001;425-430.
46. Bittner V. Estrogens, lipids, and cardiovascular disease no easy answers . J Am Coll Cardiol. 37:2001;431-433.
47. Davidson M.H., Testolin L.M., Maki K.C., von Duvillard S., Drennan K.B. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med. 157:1997;1186-1192.
48. Sbarouni E., Kyriakides Z.S., Kremastinos D.T. The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease. J Am Coll Cardiol. 32:1998;1244-1250.
49. Walsh B.W., Kuller L.H., Wild R.A., Paul S., Farmer M., Lawrence J.B., Shah A.S., Anderson P.W. Effects of raloxifene on serum lipid and coagulation factors in healthy postmenopausal women. JAMA. 279:1998;1445-1451.
50. Love R.R., Wiebe D.A., Feyzi J.M., Newcomb P.A., Chappell R.J. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst. 86:1994;1534-1539.
51. Austin M.A., Selby J.V. LDL subclass phenotypes and the risk factors of the insulin resistance syndrome. Int J Obes. 19:(suppl 1):1995;S22-S26.
52. Walden C.E., Knopp R.H., Wahl P., Beach K.W., Strandness E. Jr. Sex differences in the effect of diabetes mellitus on lipoprotein triglyceride and cholesterol concentrations. N Engl J Med. 311:1984;953-959.
53. Pernerstorfer-Schoen H., Jilma B., Perschler A., Wichlas S., Schindler K., Schindl A., Rieger A., Wagner O.F., Quehenberger P. Sex differences in HAART-associated dyslipidaemia. AIDS. 15:2001;725-734.
54. Anderson K.M., Castelli W.P., Levy D.L. Cholesterol and mortality 30 years of follow-up from the Framingham Study . JAMA. 257:1987;2176-2180.
55. Castelli W.P., Garrison R.J., Wilson P.W.F., Abbott R.D., Kalousian S., Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 256:1986;2835-2838.
56. Sharrett A.R., Ballantyne C.M., Coady S.A., Heiss G., Sorlie P.D., Catellier D., Patsch W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins A-1 and B, and HDL density subfractions. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 104:2001;1108-1113.
57. Brunner D., Weisbort J., Meshulam N., Schwartz S., Gross J., Saltz-Rennert H., Altman S., Loebl K. Relation of serum total cholesterol and high-density lipoprotein cholesterol percentage to the incidence of definite coronary events twenty-year follow-up of the Donolo-Tel Aviv Prospective Coronary Artery Disease Study . Am J Cardiol. 59:1987;1271-1276.
58. Bass K.M., Newschaffer C.J., Klag M.J., Bush T.L. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med. 153:1993;2209-2216.
59. Gordon D.J., Rifkind B.M. High density lipoprotein - the clinical implications of recent studies. N Engl J Med. 321:1989;1311-1316.
60. Austin M. Plasma triglyceride and coronary heart disease. Arterioscler Thromb. 11:1991;2-14.
61. Lerner D.J., Kannel W.B. Patterns of coronary heart disease morbidity and mortality in the sexes a 26-year follow-up of the Framingham population . Am Heart J. 111:1986;383-390.
62. Manolio T.A., Pearson T.A., Wenger N.K., Barrett-Connor E., Payne G.H., Harlan W.R. Cholesterol and heart disease in older persons and women. Review of an NHLBI Workshop. Ann Epidemiol. 2:1992;161-176.
63. Kamigaki A.S., Siscovick D.S., Schwartz S.M., Psaty B.M., Edwards K.L., Raghunathan T.E., Austin M.A. Low density lipoprotein particle size and risk of early-onset myocardial infarction in women. Am J Epidemiol. 153:2001;939-945.
64. Mykkaenen L., Kuusisto J., Haffner S.M., Laakso M., Austin M.A. LDL size and risk of coronary heart disease in elderly men and women. Arterioscler Thromb Vasc Biol. 19:1999;2742-2748.
65. Bostom A.G., Gagnon D.R., Cupples L.A., Wilson P.W.F., Jenner J.L., Ordovas J.M., Schaefer E.J., Castelli W.P. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation. 90:1994;1688-1695.
66. Kannel W.B. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 76:1995;69C-77C.
67. Kane J.P., Malloy M.J., Ports T.A., Phillips N.R., Diehl J.C., Havel R.J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 264:1990;3007-3012.
68. Byington R.P., Evans G.W., Espeland M.A., Applegate W.B., Hunninghake D.B., Probstfield J., Furberg C.D., for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group . Effects of lovastatin and warfarin on early carotid atherosclerosis. Sex-specific analyses. Circulation. 100:1999;E14-E17.
69. Miettinen T.A., Pyorala K., Olsson A.G., Musliner T.A., Cook T.J., Faergeman O., Berg K., Pedersen T., Kjekshus J., Scandinavian Simvastatin Survival Study (4S) . Cholesterol lowering therapy in women and older persons with myocardial infarction or angina pectoris. Circulation. 96:1997;4211-4218.
70. Lewis S.J., Sacks F.M., Mitchell J.S., Lewis S.J., Sacks F.M., Mitchell J.S., East C., Glasser S., Kell S., Letterer R., et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction the Cholesterol and Recurrent Events (CARE) Trial . J Am Coll Cardiol. 32:1998;140-146.
71. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
72. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
73. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 279:1998;1615-1622.
74. LaRosa J.C., He J., Vupputuri S. Effect of statins on risk of coronary disease a meta-analysis of randomized controlled trials . JAMA. 282:1999;2340-2346.